Mobile

A PHASE 2b MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, DOSE-RANGING STUDY EVALUATING THE EFFICACY AND SAFETY OF PD 0299685 FOR THE TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS...

Mise à jour : Il y a 4 ans
Référence : EUCTR2006-001322-25

A PHASE 2b MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, DOSE-RANGING STUDY EVALUATING THE EFFICACY AND SAFETY OF PD 0299685 FOR THE TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE Estudio en fase 2b multicéntrico, doble ciego, controlado con placebo, con grupos paralelos y de determinación de dosis para evaluar la eficacia y la seguridad de PD-0299685 en el tratamiento de los síntomas vasomotores moderados o intensos asociados a la menopausia

Femme Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

· To assess the efficacy of PD 0299685 in the treatment of moderate to severe vasomotor symptoms associated with the menopause; · To characterise the dose range and dose response relationships of PD 0299685 in the treatment of moderate to severe vasomotor symptoms associated with the menopause · To assess the safety and tolerability of PD 0299685.

Critère d'inclusion

  • Treatment of moderate to severe vasomotor symptoms (hot flushes) associated with menopause

Liens